In patients with multiple myeloma (MM) at first relapse or those refractory to one prior line of therapy, carfilzomib in combination with cyclophosphamide and dexamethasone (KCd) improves response rates vs bortezomib plus cyclophosphamide and dexamethasone (VCd), while maintenance carfilzomib following KCd prolongs progression-free survival (PFS), results from the phase II MUK fivestudy have shown.
Combination therapy with venetoclax, carfilzomib and dexamethasone (VenKd) has demonstrated promising objective response rates (ORRs) in patients with relapsed/refractory multiple myeloma (R/R MM) in an ongoing phase II study.
Salvage treatment with carfilzomib, pomalidomide and dexamethasone (KPd) is effective and safe in transplant-eligible multiple myeloma (MM) patients with refractory disease or first progression on or after treatment with bortezomib and lenalidomide, according to data from patients enrolled in the EMN02 trial.
Carfilzomib in combination with dexamethasone (Kd) is effective and safe in patients with multiple myeloma (MM) relapsing on or after lenalidomide and those with lenalidomide-refractory disease, a combined analysis of carfilzomib trials has shown.
A curative strategy for smoldering multiple myeloma (SMM) that involves induction therapy with carfilzomib, lenalidomide and dexamethasone (KRd) followed by high-dose melphalan and autologous stem cell transplantation (ASCT), KRd consolidation, and maintenance with lenalidomide and dexamethasone has demonstrated promising results in a phase II trial.
Quadruplet induction therapy with carfilzomib, cyclophosphamide, lenalidomide and dexamethasone (KCRd) improves response and progression-free survival (PFS) vs immunomodulatory triplet regimens in patients with newly diagnosed multiple myeloma (MM) eligible for autologous stem cell transplantation (ASCT), results of the Myeloma XI study have shown.
Patients with symptomatic multiple myeloma (MM) following induction and conditioning therapy and autologous stem cell transplant (ASCT) may derive survival benefit from maintenance therapy with ixazomib, according to the phase III TOURMALINE-MM3* trial.
The addition of daratumumab to lenalidomide and dexamethasone improved progression-free survival (PFS) in patients newly diagnosed with multiple myeloma (MM) who were ineligible for a stem cell transplant, according to interim results of the phase III multinational MAIA* trial.
Use of a single course of the intravenous iron preparation ferumoxytol may lead to sustained improvements in patient-reported outcomes (PROs) of individuals with iron deficiency anaemia (IDA) who had inadequate response to oral iron therapy, according to data presented at ASH 2018.
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim,
27 Nov 2019
The current standard
of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour
with a rapid disease course, consists of maximum safe surgical resection
followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and
subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian
Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the
evidence and shared their clinical experience on the use of tumour treating
fields (TTFields), a novel treatment modality for GBM.
There appears to be no significant survival difference between first-line immune checkpoint inhibitor (ICI) and carboplatin-based chemotherapy in cisplatin-ineligible metastatic urothelial carcinoma patients, according to a Taiwan study presented at the recent 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).